Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00698646 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 384
- Enrollment target
NCT00698646 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 384 participants.
The verdict
NCT00698646, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 384 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of initial treatment therapy with valsartan/hydrochlorothiazide (HCTZ) versus the initial treatment therapy with monotherapies (valsartan or HCTZ) in the very elderly patients (greater than or equal to 70 years) with stage 1 or 2 hypertension
Interventions
- DRUG Valsartan
- DRUG HCTZ
- DRUG Valsartan + HCTZ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 384 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00698646
The ClinicalTrials.gov registry entry for NCT00698646 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 384 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Valsartan is the first listed.
NCT00698646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00698646 about?
NCT00698646 is a clinical study titled "Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.". The purpose of the study is to evaluate the safety and efficacy of initial treatment therapy with valsartan/hydrochlorothiazide (HCTZ) versus the initial treatment therapy with monotherapies (valsartan or HCTZ) in the very elderly patients (greater than or equal to 70 years) with stage 1 or 2 hypert...
What is the current status of trial NCT00698646?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 384 participants. The study started on 2008-04. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00698646?
The interventions under investigation include: Valsartan (DRUG), HCTZ (DRUG), Valsartan + HCTZ (DRUG).
Who is sponsoring clinical trial NCT00698646?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.